Curis, Genentech Announce Cancer Drug Study Result
From Associated Press (March 21, 2011)
CAMBRIDGE, Mass. -- Drug developer Curis Inc. said Monday a mid-stage trial of a potential cancer treatment it is studying with Roche's Genentech unit shrank tumors in patients with an advanced form of skin cancer.
The treatment, labeled vismodegib, was tested in a study involving 104 patients with advanced basal cell carcinoma whose lesions were not appropriate for surgery. It shrank tumors in a pre-defined percentage of people in the study. A safety assessment of the drug is ongoing.
Curis, which is based in Cambridge, Mass., said Swiss drug maker Roche anticipates making at least one regulatory submission in 2011 on the drug.
The treatment, also labeled GDC-0449, also has been studied as a possible treatment for colon cancer and advanced ovarian cancer.
Shares of Curis climbed 17 percent, or 51 cents, to $3.44 in Monday morning trading.
Posted: March 2011